Meeting
2024 ASCO Genitourinary Cancers Symposium
Erectile function in patients with metastatic renal cell carcinoma treated with first-line therapy.
Authors
Ilya Tsimafeyeu
Bureau for Cancer Research - BUCARE, New York, NY
Ilya Tsimafeyeu , Ruslan Zukov , Pavel S. Borisov , Valentina Leonenko , Vladimir Kuznetsov , Anastasia Bondarenko , Yulia Tishova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 383)
DOI
10.1200/JCO.2024.42.4_suppl.383
Abstract #
383
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2020 ASCO Virtual Scientific Program
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
First Author: Shaan Dudani
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2022 ASCO Annual Meeting
First-line therapy for elderly patients with advanced renal cell carcinoma (aRCC): A systemic review and network meta-analysis.
First Author: Yu Fujiwara